caa a22 4500 606204326 CHVBK 20210128101001.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s10388-014-0478-9 doi (NATIONALLICENCE)springer-10.1007/s10388-014-0478-9 Early tumor response to induction chemotherapy or chemoradiotherapy is a significant prognostic predictor in patients with initially unresectable T4 esophageal cancer following subsequent surgery [Elektronische Daten] [Hideaki Shimoji, Hiroyuki Karimata, Tadashi Nishimaki] Background: Little is known about reliable prognostic predictors after early administration of intensive, multimodal therapies in esophageal cancer patients. We aimed to determine whether early tumor responses (ETR) to preoperative chemotherapy or chemoradiotherapy in T4 esophageal cancer patients could be significant prognostic predictors. Methods: Forty-eight patients with suspected T4 esophageal cancers were enrolled in this prospective study to test the efficacy of preoperative induction chemotherapy or chemoradiotherapy followed by esophagectomy, which was feasible in only 37 patients. We performed nested analysis of ETR as a prognostic predictor, using univariate and multivariate analyses. Results: Univariate analyses revealed that the final tumor response (p<0.001), ETR (p<0.001), dysphagia improvement (p=0.002), and post-induction therapy serum albumin levels (p=0.025) were significant prognostic predictors in the 48 patients. Pretreatment serum squamous cell carcinoma-related antigen levels (p=0.008), final tumor response (p<0.001), ETR (p=0.004), and induction therapy toxicity grading (p=0.031) were found to be prognostic predictors in 37 patients. ETR absence was associated with an unfavorably short median survival duration in both the 48 (6.4months) and 37 patients (10.2months). Final tumor response was the significant sole independent prognostic predictor in both patient groups using multivariate analyses. Conclusions: ETR is a significant prognostic predictor in T4 esophageal cancer patients who underwent induction chemotherapy or chemoradiotherapy and subsequent surgery. The Japan Esophageal Society and Springer Japan, 2014 T4 esophageal cancer nationallicence Induction therapy nationallicence Early tumor response nationallicence Shimoji Hideaki Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut Karimata Hiroyuki Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut Nishimaki Tadashi Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut Esophagus Springer Japan 12/3(2015-07-01), 233-243 1612-9059 12:3<233 2015 12 10388 https://doi.org/10.1007/s10388-014-0478-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10388-014-0478-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Shimoji Hideaki Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut NATIONALLICENCE 700 1- Karimata Hiroyuki Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut NATIONALLICENCE 700 1- Nishimaki Tadashi Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, 903-0215, Nishihara, Okinawa, Japan aut NATIONALLICENCE 773 0- Esophagus Springer Japan 12/3(2015-07-01), 233-243 1612-9059 12:3<233 2015 12 10388